Eidos Therapeutics, Inc. (EIDX)
(Delayed Data from NSDQ)
$25.98 USD
+1.19 (4.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $25.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[EIDX]
Reports for Purchase
Showing records 41 - 55 ( 55 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Yas'' Weekly Recap - What the Buy-side Reads
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Healthcare - Yas'' Weekly Recap - What the Buy Side Reads
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
AG10 Beats Tafimidis; Data Exceed Expectations
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Clock Is Ticking Until AG10 Comes Out as Best-in-Class TTR Stabilizer
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.